Corxel reports up to 11.5% weight loss for oral GLP-1 CX11 in Phase 2 obesity trials

Details of the Phase 2 trial finding appeared in news filings dated 26 October 2026.

Sarah Lindqvist-Park

Clinical Nutrition Writer

Share on X

Stands on 2 placed sources from 2 publishers.

Corxel stated its lead oral GLP-1 drug CX11 produced up to 11.5% body weight loss at 36 weeks in Phase 2 obesity trials ^[1]. Corxel Pharmaceuticals is developing oral drug candidates, with CX11 as its lead product. The drug is being investigated for obesity, type 2 diabetes and cardiometabolic conditions ^[2].

Proof2 sources · 2 publishers · signed

What this stands on

Corxel stated its lead oral GLP-1 drug CX11 produced up to 11.5% body weight loss at 36 weeks in Phase 2 obesity trials. · MedCity News
Corxel Pharmaceuticals is developing oral drug candidates, with lead product CX11 targeting obesity, type 2 diabetes and cardiometabolic conditions. · Investing.com

We could not place any of them by their address. None is an official body: that part stands on reporting, not on the underlying document or transcript.